Navigation Links
Capturing circulating cancer cells could provide insights into how disease spreads
Date:12/11/2012

ANN ARBORA glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.

Engineering and medical researchers at the University of Michigan have devised such a set-up, which they say takes advantage of cancer cells' stronger drive to settle and bind compared with normal blood cells.

Circulating tumor cells are believed to contribute to cancer metastasis, the grim process of the disease spreading from its original site to distant tissues. Blood tests that count these cells can help doctors predict how long a patient with widespread cancer will live.

As important as the castaway cells are, scientists don't know a lot about them. They're rare, at about one per billion blood cells. And they are not all identical, even if they come from the same tumor. Existing tools for isolating them only catch certain types of cellsthose that express specific surface proteins or are larger than normal blood cells.

For example, the commonly used, FDA-approved CellSearch system uses antibody- coated magnetic beads to seek out tumor cells and bind to them. But not all circulating tumor cells express the proteins these antibodies recognize. It is possible that the most dangerous ones, known as cancer stem or progenitor cells, may have shed that tell-tale coat, thereby evading approaches that rely on antibodies.

The researchers say their system could likely trap these stealth cancer stem cellsa feat no research team has accomplished yet.

"Our system can capture the majority of circulating tumor cells regardless of their surface proteins or their physical sizes, and this could include cancer progenitor or initiating cells," said Jianping Fu, assistant professor of mechanical engineering and biomedical engineering and a senior author of a paper on the technique published online in ACS Nano.

Fu and his engineering colleagues teamed up with U-M senior cancer researcher and breast cancer clinician Dr. Sofia Merajver and her team. This multidisciplinary group believes that while the device could one day improve cancer diagnosis and prognosis, its first uses would be for researchers to isolate live circulating tumor cells from blood specimens and study their biological and physical properties.

"Understanding the physical behavior and nature of these circulating tumor cells will certainly help us understand better one of the most difficult questions in cancer biologythe metastatic cascade, that is, how the disease spreads," Fu said. "Our system could provide an efficient and powerful way to capture the live circulating tumor cells and use them as a surrogate to study the metastatic process."

But capturing them, as challenging as it has proven to be, is only the beginning, said Merajver, who has spent the last 18 years studying cell signaling and the physical properties of highly aggressive cancer cells.

"The application of integrative biology is necessary to put together the story of how these cells behave in time to achieve successful metastases and thereby discover the routes to suppressing this deadly development," Merajver said. "Our collaboration with the Fu lab exemplifies the innovation needed for the war against cancerteam science from the lab all the way to the clinic."

In their experiments, the researchers used a standard and inexpensive microfabrication technique called "reactive ion etching" to roughen glass slides with a nanoscale resolution. Then, they spiked different blood samples with cancer cells derived from human breast, cervical and prostate tissues. When they poured the samples over the glass plates, the nanorough glass surfaces captured an average of 88 percent to 95 percent of the cancer cells.

Fu suggests why.

"Blood cells are intrinsically floating," Fu said. "Cancer cells including circulating tumor cells derived from solid tumors are presumably adherent cells. They can escape from the primary tumor while maintaining certain adhesion properties that allow them to attach and establish another tumor."

In other studies, researchers have noticed that circulating tumor cells tend to stick to rough surfaces. But the rough surfaces in those studies were coated with capture antibodies. These new nanorough surfaces do not require capture antibodies.

"Our method presents a significant improvement as it can be applied in principle to any cancer cell that comes from solid tumors," Fu said.

The paper is titled "Nanoroughened Surfaces for Efficient Capture of Circulating Tumor Cells without Using Capture Antibodies." The university is pursuing patent protection for the intellectual property and is seeking commercialization partners to help bring the technology to market.


'/>"/>

Contact: Nicole Casal Moore
ncmoore@umich.edu
734-647-7087
University of Michigan
Source:Eurekalert

Related medicine news :

1. Coffee May Lower Risk of Death From Mouth Cancer: Study
2. The current state of lung cancer treatment
3. Children born prematurely are at higher risk of esophageal inflammation, cancer
4. FDA OKs Expanded Use of Prostate Cancer Drug
5. Prostate cancer now detectable by imaging-guided biopsy
6. Targeted prostate biopsy has potential to improve diagnosis of prostate cancer
7. UCLA cancer scientists identify liposarcoma tumors that respond to chemotherapy
8. The Project for Natural Health Choices Inc. Issues an Advisory for Men to Consume Flavonoids in their Diet to Protect Against Prostate Cancer
9. To fight incurable metastatic breast cancer, resistance must be broken
10. Caffeinated coffee may reduce the risk of oral cancers
11. Abnormal DNA maintenance related to cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... The ... held annually in this country. The AutismOne 2016 Conference, which is being held May ... they often won’t hear elsewhere about helpful interventions and causes of chronic illness in ...
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 Vestagen Technical ... high performance apparel for healthcare and other demanding applications, ... Chief Executive Officer. He replaces Dale Pfost , ... Chairman. Mr. Bold is also joining Vestagen,s Board of ... new class of active barrier technologies that combines fluid ...
(Date:2/8/2016)... YORK, Pa. , Feb. 8, 2016  Unilife Corporation ... developer and supplier of injectable drug delivery systems, today announced ... and six months ended December 31, 2015 after market close ... not scheduled a conference call to discuss these financial results.  ... About Unilife Corporation --> About Unilife ...
(Date:2/8/2016)... -- Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko ... as president, Americas Operations, for Astellas US LLC, with ... South America , effective April 1, 2016.  Robinson previously ... in the United States -- a ... , who is retiring in June 2016.  --> ...
Breaking Medicine Technology: